분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-12-20 13:04:01 , Hit : 369
 Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

https://www.marketwatch.com/story/spark-therapeutics-shares-rise-on-fda-approval-of-new-gene-therapy-for-blindness-2017-12-19-1191742

Published: Dec 19, 2017 11:07 a.m. ET  

By Emma Court
Reporter

Spark Therapeutics Inc. ONCE, -0.22% shares rose 3% in heavy morning trade Tuesday after the company's gene therapy Luxturna was approved by the Food and Drug Administration for a rare type of inherited vision loss. Just one administration of the therapy could treat the disease, making it a major scientific breakthrough. The approval had been widely expected after an FDA committee recommended it in October, and was heralded by FDA Commissioner Scott Gottlieb as "another first in the field of gene therapy." The next, major question for the therapy is price, with some analysts projecting the cost could come close to $1 million. Gene therapies, the first of which was approved this past summer, are expected to challenge existing U.S. payment structures with their price tags, which are extremely high and cover a one-time treatment. Luxturna was approved for individuals with confirmed biallelic RPE65 mutation-associated retinal dystrophy, which is part of a group of eye disorders caused by gene mutations, can cause complete blindness in some cases and affects about 1,000 to 2,000 people in the U.S. Spark shares have plummeted 41.5% over the last three months, compared with a 7.2% rise in the S&P 500 SPX, -0.32% and a 10.8% rise in the Dow Jones Industrial Average DJIA, -0.15%







1267   [바이오토픽] CRISPR 특허전쟁 항소심, 브로드 연구소 승리  이성욱 2018/09/11 244
1266   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 258
1265   Ruling on gene editing crops a threat to innovation and future food security, scientists say  이성욱 2018/07/28 263
1264   Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 269
1263   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 281
1262   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 284
1261   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 293
1260   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 297
1259   Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements  이성욱 2018/07/17 298
1258   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 329
1257   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 329
1256   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 345
1255   RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches  이성욱 2018/10/18 350
1254   Keytruda Gets FDA Approval for Hepatocellular Carcinoma  이성욱 2018/11/14 350
1253   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 354
1252   Novel Two-Pronged Method Targets Cancer Cells’ Telomerase and Chromosomes  이성욱 2018/11/03 359
1251   Immunotherapy Pioneers Take 2018 Nobel Prize  이성욱 2018/10/02 365
  Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 369
1249   Checkpoint Inhibitor Generated by Synthetic DNA in Vivo  이성욱 2018/10/06 372
1248   분자수준 인체 간세포 지도 처음 작성  이성욱 2018/10/24 373

1 [2][3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN